Article Per Year (5 Year)
p-Index From 2020 - 2025
1.037
P-Index
This Author published in this journals
All Journal Berkala Ilmu Kesehatan Kulit dan Kelamin Jurnal Pengabdian Masyarakat: Humanity and Medicine Jurnal RSMH Palembang Conferences of Medical Sciences Dies Natalis Media Dermato-Venereologica Indonesiana
Nopriyati
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Agen Biologik Psoriasis Terkini Nopriyati; Reza Mayasari
Conferences of Medical Sciences Dies Natalis Vol. 1 No. 1 (2019): Conferences of Medical Sciences Dies Natalis Faculty of Medicine Universitas Sr
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1048.277 KB)

Abstract

Psoriasis is a chronic inflammatory skin disease with genetic basis, characterized by complex alterations in epidermal growth and differentiation and multiple biochemical, immunologic, and vascular abnormalities. Standard systemic therapies, such as methotrexate, cyclosporine, and acitretin very effective for psoriasis, but associated with significant toxicities. Survey of psoriasis patients in United States shows they have expressed a high level of dissatisfaction with them. Over the past decade, biologic therapies developed as optional therapy of psoriasis. No definition on biologics for psoriasis categories them in old and new therapies. The oldest group of biologics encompasses molecules that target the activation and migration of T cells, alefacept and efalizumab. Therefore, biologics targeting TNFα were developed, and often referred to as first generation biologics, such as etanercept, infliximab, and adalimumab. Second generation biologics emerged from 2009 with antibodies targeting the IL-23/ Th17 pathway. The new biologic agent therapies, like ustekinumab which have targeted in IL-12/ IL-34p40 pathway, secukinumab in IL-17A pathway, ixekizumab in IL-17A pathway, and brodalumab in IL-17RA pathway were developmented in the next year.
Pelatihan pemeriksaan prevention of disability (POD) kusta pada tenaga Kesehatan dan kader di Kabupaten Prabumulih Nopriyati; Rusmawardiana; Argentina, Fifa; Deddy; Antonius, Cayadi Sidarta; Setiawan, Ivon; Veronica
Jurnal Pengabdian Masyarakat: Humanity and Medicine Vol 4 No 1 (2023): Jurnal Pengabdian Masyarakat: Humanity and Medicine
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/Hummed.V4I1.96

Abstract

Leprosy is a chronic granulomatous infection caused by Mycobacterium leprae. Leprosy infects skin, mucosa and peripheral nerves causing loss of skin sensation with or without skin lesions. Clinical feature of leprosy is highly variable, and can resemble a variety of lesions present in other diseases. Differential diagnosis of skin lesions is so broad that it can lead to misdiagnosis. Based on data from the World Health Organization (WHO) in 2018, it was reported that the number of new cases of leprosy in the world was 210,671 cases, with a new case detection rate of 2.77 per 100,000 population. Indonesia is ranked third in the world as a country with the most new cases of leprosy after India and Brazil. Lack of knowledge of health workers and cadres affects the number of leprosy cases found. This community service activity was carried out with the aim of providing counseling regarding early leprosy examination to health workers and cadres in Prabumulih. The activity was coordinated by Dermatology, Venereology, and Aesthetics Department, Faculty of Medicine, Sriwijaya University, in collaboration with AR Bunda Hospital Prabumulih. At the end of the activity the participants had a better understanding of leprosy and the steps for early leprosy examination. This activity is useful for increasing the knowledge of health workers and cadres about leprosy and how to check for leprosy.
Effect of Autologous Serum Therapy (AST) as Adjuvant Management in Morphea: A Pilot Study Nopriyati; Hasbiallah Yusuf; Ahmad Ligar Suherman
Jurnal RSMH Palembang Vol. 5 No. 1 (2024): Jurnal RSMH Palembang
Publisher : RSUP Dr Moh Hoesin Palembang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/jrp.v5i1.63

Abstract

Morphea, or localized scleroderma, is a chronic autoimmune disease characterized by sclerosis of the skin, subcutaneous tissue, and bones. Morphea therapy targets the inflammatory component, cytokine release and collagen activation and deposition. The mechanism of action of autologous serum therapy (AST) is based on the principle of induction of desensitization or tolerance to pro-inflammatory signals. The patient's clinical improvement criteria were calculated using the localized scleroderma cutaneous assessment tool (LoSCAT) based on physical examination. This study used a one group pre-test – post-test experimental design on morphea patients at the Dermatology, Venereology, and Aesthetics (DVE) Polyclinic, Allergy and Immunology Subdivision in Dr. Mohammad Hoesin General Hosptial (RSMH) Palembang in May-October 2023. This study included 7 morphea patients who met the inclusion criteria for AST injection in 8 weeks duration. The Dermatology Life Quality Index (DLQI) assessment carried out before the AST and after the 8th AST showed that all patients experienced improvements in quality of life after 8 weeks. There was a decrease in LoSCAT scores in 5 patients (71.4%), while there was no change in LoSCAT scores in 2 patients (28.6%). Side effects of pain at the AST injection site in 3 patients (42.8%) were tolerable without painkillers, while other patients did not experience any side effects. The paired T-test statistical test on patients before AST and after AST treatment for 8 weeks showed that there was a significant difference in the mean DLQI and LoSCAT with p-value respectively 0.003 and 0.032. There is a significant difference in the mean DLQI and LoSCAT in study patients before AST and after AST for 8 weeks. There were side effects in the form of local pain at the AST injection area in 3 patients which were well tolerated without painkillers.
Update Management of Atopic Dermatitis Sari, Indri Widya; Diba, Sarah; Nopriyati; Athuf Thaha; Raden Pamudji; Fitriani
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 36 No. 3 (2024): DECEMBER
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bikk.V36.3.2024.213-221

Abstract

Background: Atopic dermatitis (AD) is a chronic recurrent skin disease that is very complex due to impaired skin barrier function in the form of xerosis, chronic eczematous lesions, and itching, commonly found in infants and children. Pathogenesis is thought to be the interaction of genetic factors, immune dysfunction, epidermal barrier dysfunction, and the role of the environment and infectious agents. Approach the disease by performing etiopathogenesis algorithms, clinical manifestations, diagnosis, and treatment. Based on the 2013 Asia-Pacific consensus, AD management guidelines using the 5-pillar principle have long been used. Currently, the European consensus in 2018 has developed new guidelines for AD management. Purpose: To provide an updated treatment for AD. Review: The ethiopathogenesis of AD is influenced by genetics, skin barrier disorders, and immune response disorders. Updated management of the European consensus in 2018 includes education, avoidance of precipitating factors, psychosomatic counseling, optimization of skin barrier function with moisturizers, anti-inflammatory and antimicrobial administration, allergen-specific immunotherapy, complementary and alternative drugs, phototherapy, and controlling the itch-scratch cycle with anti-itch in pediatric and adult AD patients. AD may affect patients’ quality of self-esteem. In general, patients expect higher. Conclusion: AD affects the psychosocial aspects of patients. Updated management of AD adequately improves the quality of life.
KEBERHASILAN TERAPI PEMFIGUS VULGARIS DENGAN STEROID-SPARING AGENT MIKOFENOLAT SODIUM DAN AUTOHEMOTERAPI Aldona, Wenty Septa; Nopriyati; Nugroho, Suroso Adi; Budiamal, Susanti
Media Dermato-Venereologica Indonesiana Vol 52 No 1 (2025): Media Dermato Venereologica Indonesiana
Publisher : Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33820/mdvi.v52i1.518

Abstract

Pendahuluan: Pemfigus vulgaris (PV) merupakan penyakit autoimun ditandai vesikel dan bula pada kulit dan mukosa akibat reaksi autoantibodi terhadap desmoglein (Dsg) 1 dan 3. Terapi lini pertama kortikosteroid (KS) sistemik. Terapi KS memiliki banyak efek samping sehingga diperlukan sparing agent. Pada kasus ini menggunakan sparing agent mikofenolat sodium (MPS) dan autohemoterapi (AHT). Laporan ini bertujuan mengetahui efektivitas MPS dan AHT sebagai sparing agent pada PV. Kasus: Perempuan, 37 tahun dengan lepuh kendur mudah pecah menjadi lecet disertai keropeng coklat-kehitaman pada wajah, leher, badan, kedua lengan dan tungkai. Pemeriksaan histopatologik ditemukan row of tombstones suprabasal, dan direct immunofluorescence (DIF) ditemukan chicken wire pattern interselular. Pasien didiagnosis PV dan diterapi KS sistemik dengan sparing agent MPS dan AHT. Kami melaporkan kasus jarang PV pada usia 37 tahun. Diskusi: Penggunaan sparing agent untuk mengurangi efek samping, mempercepat tapering off, perbaikan klinis dan remisi. Mikofenolat sodium digunakan karena efek samping minimal dan memberikan hasil baik. Autohemoterapi sebagai imunoterapi dengan menyuntikkan darah pasien kembali pada pasien, dapat digunakan pada penyakit vesikobulosa autoimun karena dapat menurunkan kadar autoantibodi. Kesimpulan: Kombinasi KS sistemik, MPS dan AHT memberikan hasil yang memuaskan. Pasien mengalami remisi awal pada pekan ke-2 dan remisi komplet dalam 5 bulan. 
Co-Authors Ahmad Ligar Suherman Aldona, Wenty Septa Antonius, Cayadi Sidarta aryani, Inda astri Athuf Thaha Deddy Diba, Sarah Fifa Argentina Fitriani Hasbiallah Yusuf Nugroho, Suroso Adi Raden Pamudji Reza Mayasari Rusmawardiana Rusmawardiana, Rusmawardiana Sari, Indri Widya Setiawan, Ivon Susanti Budiamal Veronica